Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs

Background and Objectives To evaluate brain volume changes caused by different subclasses of anti–β-amyloid (Aβ) drugs trailed in patients with Alzheimer disease. Methods PubMed, Embase, and ClinicalTrials.gov databases were searched for clinical trials of anti-Aβ drugs. This systematic review and meta-analysis included adults enrolled in randomized controlled trials of anti-Aβ drugs (n = 8,062–10,279). The inclusion criteria were as follows: (1) randomized controlled trials of patients treated with anti-Aβ drugs that have demonstrated to favorably change at least one biomarker of pathologic Aβ and (2) detailed MRI data sufficient to assess the volumetric changes in at least one brain region. MRI brain volumes…

• E
  Eisai
• NI
  National Institutes of Health
• NI
  National Institute on Aging